Nominee Name/Nominee Company NameIndustry Disrupter Award: Rhaeos
Finalist for the:Industry Disrupter
About the Nominee:Rhaeos, Inc. is a VC backed, clinical stage medical device company developing FlowSense, a platform technology and a noninvasive wireless, wearable skin patch that can assess and monitor fluid flow peripherally throughout the body. The company is initially targeting hydrocephalus, a life threatening condition caused by an abnormal accumulation of cerebrospinal fluid (CSF). Implantable shunts, the gold standard treatment, often fail, leading to multiple trips to the emergency room and repeat surgeries. There is no technology available today that can easily assess CSF flow in shunts wirelessly, bedside, and without capital equipment until now. Rhaeos has raised >$8M in financing, received FDA breakthrough designation, published clinical data in Science and Nature family journals, and is on track for initial market entry in late .
Why they should win:Rhaeos develops FlowSense, an FDA designated breakthrough technology, that is a proprietary wireless, noninvasive and wearable sensor mounted on skin with size of a standard adhesive bandage to detect the presence and magnitude of fluid flow throughout the human body for various chronic conditions with no cure (e.g. hydrocephalus, dialysis, lymphedema, skin flap reconstruction, etc.). The technology has been validated in peer reviewed medical journals and ongoing clinical trials.